ImmunityBio, Inc.

ANKTIVA® plus BCG has received a positive recommendation for marketing authorization in the EU for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary tumors. The recommendation reflects the EMA’s determination that earlier patient access is warranted, and represents an important step forward for individuals with BCG-unresponsive disease – an area with otherwise limited treatment options. Learn more: https://lnkd.in/gwE7tcNq

While the exact cause of glioblastoma remains unknown, several risk factors have been linked to increased risk - including age, gender, prior exposure to radiation, and rare genetic conditions. For many patients, however, glioblastoma develops without a clear identifiable cause. At ImmunityBio, we're conducting clinical research to better understand glioblastoma and evaluate investigational therapies that may offer new options for patients facing this difficult diagnosis. To learn more about our research, visit https://lnkd.in/gm8a_Bfh

The 2024 National Health Interview Survey shows a powerful truth: if lung cancer screenings were to reach 100%, 62,000 lives could be saved in a mere five years. As we recognize Lung Cancer Awareness Month, insights like this reinforce why ImmunityBio is investing in new approaches that aim to expand treatment options and address the challenges in lung cancer care.

A recent Harris survey found that a vast majority of patients with non-muscle invasive bladder cancer (NMIBC) see intravesical chemotherapy as a last resort, whereas 72% of immunotherapy recipients are satisfied with the duration of positive treatment effects. With patients at the forefront, ImmunityBio continues to focus on innovative approaches designed to preserve bladder function and improve quality of life for those facing difficult treatment decisions. Read more here: https://lnkd.in/gNECy4Rt

Hope moves science forward. This month, we honor the strength of the bladder cancer community and remain committed to transforming the treatment landscape through therapies that empower the immune system to fight cancer more effectively.

We reported another quarter of strong results, driven by increased demand for ANKTIVA® and continued progress across our immunotherapy pipeline. In Q3 2025, we achieved significant year-to-date unit growth of 467% and $75 million in total product sales, reflecting growing adoption in BCG-unresponsive non-muscle invasive bladder cancer. As we close out the year, we remain committed to expanding access to our therapies, advancing ongoing trials across multiple indications, and executing our long-term vision to transform how cancer is treated. Read the full release, including important cautionary statements about forward-looking information: https://lnkd.in/gN5nUTh9